Mason RP, Jacob RF. Eicosapentaenoic acid (EPA) reduces glucose-induced small dense low-density lipoprotein oxidation in vitro in a manner distinct from other triglyceride-lowering agents and vitamin E [abstract 705-P]. Diabetes. 2015;64(suppl 1):A178-A179. Posting of the abstract is pending permission by the Journal Diabetes.

Mason RP, Jacob RF. Eicosapentaenoic acid (EPA), but not other TG-lowering agents, reduces cholesterol domain levels in atherosclerotic-like model membranes [abstract 176]. J Clin Lipidol. 2015;9:466.

Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract 172]. J Clin Lipidol. 2015;9:463-4. 

Stirtan WG, Braeckman RA, Bays HE, Ballantyne CM, Soni PN, Juliano RA. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract 173]. J Clin Lipidol. 2015;9:464.

Stirtan WG, Braeckman RA, Bays HE, Ballantyne CM, Soni PN, Juliano RA. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract 173]. J Clin Lipidol. 2015;9:464. 

Stirtan WG, Braeckman RA, Bays HE, Ballantyne CM, Soni PN, Juliano RA. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract 173]. J Clin Lipidol. 2015;9:464. 

Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract 172]. J Clin Lipidol. 2015;9:463-4.

Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract 172]. J Clin Lipidol. 2015;9:463-4.